Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
06/2014
06/18/2014CN102532316B Anti-vWF (von Willebrand factor) monoclonal antibody and application thereof
06/18/2014CN102369285B Beta-gI-IgG intron for enhanced anti-IGF1R expression
06/18/2014CN101970488B Humanized antibody molecules specific for il-31
06/18/2014CN101918446B Methods for inhibiting the binding of endosialin to ligands
06/18/2014CN101675075B Recombinant anti-epidermal growth factor receptor antibody compositions
06/18/2014CN101479296B TRAIL receptor-binding agents and uses of the same
06/18/2014CN101155830B Antibodies that bind to epha2 and methods of use thereof
06/17/2014US8754195 Antibody formulations
06/17/2014US8754190 Controlled release from macromolecular conjugates
06/17/2014US8754049 Organic compound for the regulation of vectorial ion channels
06/17/2014US8754046 MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1
06/17/2014US8753843 Antibodies to IL-17A
06/17/2014US8753839 Compositions and methods for crystallizing antibodies
06/17/2014US8753828 Humanized anti-CCR2 antibodies and methods of use therefor
06/17/2014US8753822 Neoepitope detection of disease using protein arrays
06/17/2014US8753650 Staphylococcus aureus proteins and nucleic acids
06/17/2014US8753637 Binding partners for the thyrotropin receptor and uses thereof
06/17/2014US8753634 Anti-IL-6 receptor antibodies and methods of use
06/17/2014US8753633 Human antibodies that bind human TNFα
06/17/2014US8753632 Antibodies to modified human IGF-1/E peptides
06/17/2014US8753631 Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
06/17/2014US8753629 Optimized Fc variants
06/17/2014US8753628 Optimized Fc variants
06/17/2014US8753627 Anti-activin a antibodies and uses thereof
06/17/2014US8753623 Influenza vaccine
06/17/2014CA2709354C Anti-amyloid antibodies and uses thereof
06/17/2014CA2635599C Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
06/17/2014CA2622603C Method for preparing immunoglobulin libraries
06/17/2014CA2601936C Epidermal growth factor receptor mutations
06/17/2014CA2366062C Human dickkopf-related protein and nucleic acid molecules and uses therefor
06/12/2014WO2014089500A1 A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
06/12/2014WO2014089493A1 Antibodies against factor xii and uses thereof
06/12/2014WO2014089354A1 Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
06/12/2014WO2014089335A2 Bcma antigen binding proteins
06/12/2014WO2014089209A2 Blood-brain barrier (bbb) penetrating dual specific binding proteins
06/12/2014WO2014089193A1 Anti-fgfr2 antibodies
06/12/2014WO2014089152A1 Hiv-1 env-binding antibodies, fusion proteins, and methods of use
06/12/2014WO2014089113A1 Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
06/12/2014WO2014089111A1 Compositions and methods for antibodies targeting epo
06/12/2014WO2014087863A1 Anti-folr1 antibody
06/12/2014WO2014087810A1 Anti-vasohibin 2 antibody
06/12/2014WO2014087626A1 Sema5b peptides and vaccines containing the same
06/12/2014WO2014087299A1 Engineered monomeric antibody fragments
06/12/2014WO2014087010A1 IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
06/12/2014WO2014087007A1 Plasmodium falciparum neutralizing antibodies
06/12/2014WO2014087005A1 Antibody against the protein trio and its method of production
06/12/2014WO2014086496A1 Dual targeting
06/12/2014WO2014086365A1 Anti-pad2 antibodies and treatment of autoimmune diseases
06/12/2014WO2014058875A3 Combination therapies and uses for treatment of demyelinating disorders
06/12/2014WO2014031859A9 Compositions and methods relating to blood-based biomarkers of breast cancer
06/12/2014WO2013070776A8 Neutralizing gp41 antibodies and their use
06/12/2014US20140163208 Collection and methods for its use
06/12/2014US20140162904 Library of Cells That Produce Antibodies That Comprise Non-Naturally Paired IGH and IGL Variable Domains
06/12/2014US20140162889 Composition or kit for making a prognosis of liver cancer, and method for making a prognosis of liver cancer
06/12/2014US20140162357 Methods for generation of antibodies
06/12/2014US20140162356 Monoclonal antibodies with enhanced adcc function
06/12/2014US20140162317 Isoform entriched antibody preparation and method for obtaining it
06/12/2014US20140162316 Anti-GLP-1R Antibodies and Their Uses
06/12/2014US20140162296 Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof
06/12/2014US20140162295 Method and Biomarker for Detecting of Acute Kidney Injury
06/12/2014US20140162292 Reagent For Diagnosing Tumor, Pharmaceutical Composition, And Screening Method
06/12/2014US20140161875 Antibodies to phosphorylated tau aggregates
06/12/2014US20140161870 Antibody Specific for CD22 and Methods of Use Thereof
06/12/2014US20140161828 Bcma antigen binding proteins
06/12/2014US20140161825 Methods of Treating Acute Myeloid Leukemia by Blocking CD47
06/12/2014US20140161823 Compositions and methods for diagnosing and treating an inflammation
06/12/2014US20140161822 Anti-hemagglutinin antibodies and methods of use
06/12/2014US20140161821 Treatment with anti-pcsk9 antibodies
06/12/2014US20140161817 Stable dual variable domain immunoglobulin protein formulations
06/12/2014US20140161816 Anti- tnf antibodies, compositions, methods and uses
06/12/2014US20140161814 Uses of monoclonal antibody 8h9
06/12/2014US20140161812 Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
06/12/2014US20140161809 Diagnostic and therapeutic target
06/12/2014US20140161808 Antibodies that bind novel pcsk9 variants
06/12/2014US20140161807 Methods of promoting cns neuronal repair by inhibiting lrp-1
06/12/2014US20140161806 Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
06/12/2014US20140161805 Methods for Manipulating Phagocytosis Mediated by CD47
06/12/2014US20140161804 Bispecific immunobinders directed against tnf and il-17
06/12/2014US20140161803 Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
06/12/2014US20140161802 Selective elimination of erosive cells
06/12/2014US20140161800 Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
06/12/2014US20140161799 Therapeutic CD47 Antibodies
06/12/2014US20140161798 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
06/12/2014US20140161796 Single chain proteins with c-terminal modifications
06/12/2014US20140161794 Anti-vla-4 antibodies
06/12/2014US20140161793 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
06/12/2014US20140161792 Rhamno-Polysaccharide From Enterococcus Faecium Clonal Complex 17 and Uses Thereof
06/12/2014US20140161790 Engineered immunoglobulins with extended in vivo half-life
06/12/2014US20140161724 Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides
06/11/2014EP2741085A1 Method for detecting pancreatic cancer
06/11/2014EP2740798A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740796A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740795A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740794A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740793A1 Drug composition for cancer treatment and/or prevention
06/11/2014EP2740744A2 SP35 antibodies and uses thereof
06/11/2014EP2740743A2 Bispecific fusion antibodies with enhanced serum half-life
06/11/2014EP2740742A1 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
06/11/2014EP2740490A1 Treatment of proliferative disorders using antibodies to PSMA
06/11/2014EP2739740A1 Humanized universal light chain mice
1 ... 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 ... 1494